Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Gilead’s Lenacapavir Launch Sparks Investor Surge and Market‑Access Wins

Gilead’s launch of lenacapavir in sub‑Saharan Africa signals a major HIV prevention breakthrough and a strong investment play as options surge and market access expands.

Lisa Martinez

20/11/2025, 08:12

4 minutes to read

How Daiichi Sankyo Is Dominating TNBC & Immunotherapy Markets for 10‑Year Growth

Explore how Daiichi Sankyo’s oncology and immunotherapy strategy drives 10‑year NPV of $2.5 billion, tackles TNBC patent cliffs, and targets M&A for growth.

Lisa Martinez

18/11/2025, 09:01

4 minutes to read

Alnylam’s RNA‑Therapeutics Strategy: Navigating Patents, Pricing, and Market Expansion

Alnylam’s siRNA strategy blends cutting‑edge RNA tech with value‑based pricing and HTA wins to capture high‑margin markets, from cardiology to Huntington’s disease.

Lisa Martinez

17/11/2025, 09:14

4 minutes to read

Merck’s $9 B Bid for Cidara Boosts Antiviral Pipeline, Targets Flu Market Share

Merck’s $9 billion buy of Cidara Therapeutics adds a Phase‑III influenza prophylactic, boosting its antiviral pipeline and protecting against patent cliffs while promising 3.5‑year payback.

Lisa Martinez

16/11/2025, 11:39

4 minutes to read

Johnson & Johnson’s Q1 2025 Performance: Revenue Growth, Patent Strategies & Vision‑Tech Expansion

Johnson & Johnson’s latest earnings reveal steady growth from pharma, devices, and vision—yet patent cliffs loom. Our deep dive shows how market‑access, biosimilar strategy and targeted M&A could sustain its earnings and keep investors confident.

Lisa Martinez

14/11/2025, 07:11

5 minutes to read

How Mettler‑Toledo’s Precision Instruments Drive Pharma Growth & M&A Potential

Explore how Mettler‑Toledo’s precision weighing tech boosts pharma R&D, drives market gains, and positions it for strategic biotech partnerships and post‑patent‑cliff growth.

Lisa Martinez

12/11/2025, 08:11

4 minutes to read

Haleon’s Chair Shift: New Leadership, Market Strategy, & M&A Outlook

Haleon PLC’s board shift—Sir Dave Lewis steps down, Vindi Banga becomes chair—brings new focus on value‑based pricing, patent‑cliff strategy and M&A to safeguard growth and shareholder value.

Lisa Martinez

11/11/2025, 11:36

4 minutes to read

Grifols Q3 2025: 12% Revenue Growth, 112% Profit Surge, and Future M&A Strategy

Grifols’ Q3 2025 earnings show a 12% revenue rise, double‑digit profit jump, and 8% revenue outlook hike, driven by plasma‑derived therapeutics and a strategic focus on niche haemostasis markets and M&A opportunities.

Lisa Martinez

05/11/2025, 07:42

3 minutes to read

AbbVie’s Growth Momentum: Musculoskeletal Oncology, M&A, and Patent‑Cliff Strategy Boosts Analyst Confidence

AbbVie’s musculoskeletal oncology focus, strong cash flow and strategic M&A plans are driving bullish analyst sentiment and higher price targets despite looming patent cliffs.

Lisa Martinez

05/11/2025, 07:27

3 minutes to read

Haleon Q3 Results: 3.4% Revenue Growth, Oral‑Health Surge Drives Outlook

Haleon PLC’s Q3 shows modest revenue growth but missed earnings targets; key insights reveal how Sensodyne’s 7 % sales lift, patent strategy, and digital expansion shape the company’s long‑term outlook.

Lisa Martinez

01/11/2025, 12:07

5 minutes to read

Older articles